Stock Price & Analysis

The S1 support level for CGTX Stock is $0.62 ,The R1 resistant level for CGTX Stock is $0.79.

As of the end of day on 2025-02-06, the price of CGTX Stock was $0.649.

The target price for CGTX Stock according to analyst rating is 5.50, with the highest price target at 9.00 and the lowest at 1.50. Analysts have a Strong Buy rating on CGTX Stock overall.

The market cap of CGTX is $26.6M.

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It is focused on developing a pipeline of small molecule product candidates that targets the sigma-2 receptor (S2R) complex, a key regulator of the cellular damage response for diseases, such as Alzheimer’s disease (AD), dry age-related macular degeneration (dry AMD), geographic atrophy, and other conditions. The Company’s lead product candidate, CT1812, is an orally delivered, small molecule modulator designed to penetrate the blood-brain barriers to the S2R complex, and through its modulation, S2R restores the normal function of synapses, as well as critical cellular processes, such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling lipid membrane-bound protein trafficking, and others.

CGTX has a total of 25 employees.